Two-Drug sequence aims to clear CLL cells and let patients stop treatment
NCT ID NCT07682415
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This phase 2 trial tests a treatment plan for people with newly diagnosed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Participants first take zanubrutinib alone for 12 cycles, then add sonrotoclax for another 12 cycles. The goal is to see if this sequence can make the cancer undetectable in the blood and allow low-risk patients to stop all treatment. The study also monitors side effects and immune function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanubrutinib and sonrotoclax
What this could lead to
If successful, this treatment sequence could offer a time-limited therapy that clears CLL/SLL cells deeply, potentially allowing patients to stop treatment and stay in remission.
What could go wrong
This is an early-phase trial with only 60 participants, so results may not apply to all patients. The combination may cause side effects, and the high-risk group still needs ongoing maintenance therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLL / SLL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Lisaftoclax for Indolent Lymphoma Trial (NCT07459608)
- LP-168 for B-Cell Cancers: Phase 1 Trial (NCT04775745)
- Rocbrutinib vs Pirtobrutinib for CLL/SLL Trial NCT07342478
- Venetoclax + Acalabrutinib for Relapsed CLL Tria NCT04523428
- Epcoritamab Consolidation for CLL/SLL Trial NCT07108998
- ZE50-0134 Phase 1 Trial for CLL/SLL (NCT06708897)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Blood Disease Hospital of Chinese Academy of Medical Sciences (Institute of Hematology, CAMS)
Tianjin, Tianjin Municipality, 300000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
Henan Cancer Hospital
Zhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Qilu Hospital of Shandong University
Jinan, Shandong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shenzhen Second People's Hospital
Shenzhen, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••